Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. (Q51681817)

9 April 2018

title

Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients. (English)

1 reference

9 April 2018

1 reference

1 reference

Chee M Ng

1

1 reference

9 April 2018

A Patnaik

2

1 reference

9 April 2018

M Beeram

3

1 reference

9 April 2018

C C Lin

4

1 reference

9 April 2018

C H Takimoto

5

1 reference

9 April 2018

publication date

8 July 2010

1 reference

9 April 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

9 April 2018

volume

67

1 reference

9 April 2018

issue

5

1 reference

9 April 2018

page(s)

985-994

1 reference

9 April 2018

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Mechanistic models for myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Cisplatin (cis-diamminedichloroplatinum II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1393-Y

10.1007/S00280-010-1393-Y

21 January 2018

Identifiers

DOI

1 reference

9 April 2018

1 reference

9 April 2018